MyFinsight
Home
Blog
About
Contact
Download
Download image
Stock-based compensation
$41,316K
Depreciation
$36,072K
Amortization of intangibles
$31,752K
Impairment charges (note 3
and note 7)
$27,753K
Non-cash operating lease
expense
$6,752K
Amortization of convertible
debt discount
$1,910K
Prepaid and other assets
-$1,555K
Amortization of debt issuance
costs
$87K
Loss (gain) on
disposal of assets, net
-$31K
Net cash provided by
(used in) operating...
$5,230K
Canceled cashflow
$141,998K
Net change in cash
and cash...
-$207,394K
Canceled cashflow
$5,230K
Issuance of common stock,
net
$962K
Proceeds from maturities
of marketable...
$20,060K
Proceeds from assets held
for sale, net of...
$2,066K
Net loss
-$108,025K
Accrued compensation
-$15,665K
Accounts receivable, net
$6,178K
Accounts payable,
accrued and other...
-$4,690K
Deferred income tax
liabilities, net
$3,359K
Operating lease
liabilities
-$2,215K
Inventories
$1,543K
Other adjustments
-$323K
Net cash (used in)
provided by financing...
-$200,288K
Net cash (used in)
provided by investing...
-$12,336K
Canceled cashflow
$962K
Canceled cashflow
$22,126K
Repayment of convertible
debt
$201,250K
Purchases of property and
equipment
$27,008K
Business acquisitions,
net of cash acquired
$6,454K
Purchase of equity
securities
$500K
Purchase of convertible
note
$500K
Back
Back
Cash Flow
source: myfinsight.com
NEOGENOMICS INC (NEO)
NEOGENOMICS INC (NEO)